** Shares of drugmaker BridgeBio Pharma BBIO.O rise 7.08% to $39 after market
** Co posts Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG
** Attruby is used to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail
** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024
** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets
** Stock up ~32% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。